ICER says Hemlibra is cost-effective

In a draft evidence report published Friday, the Institute for Clinical and Economic Review said Hemlibra emicizumab-kxwh from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) is a cost-saving treatment for hemophilia A patients with inhibitors.

FDA approved once-weekly subcutaneous Hemlibra in Nov. 2017 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with Factor VIII inhibitors. The bispecific mAb that binds Factor IXa and Factor X (FX) has a wholesale acquisition cost (WAC) of about $482,000 for the first year of treatment and about $448,000 for each subsequent year (see BioCentury Extra, Nov. 16, 2017)...